













Non‐adherence to therapeutic with chronic treatments may compromise patient health,
increase care costs and lead to unnecessary consultations and diagnoses, as well as additional
treatments with potentially serious side effects1‐5, which can cause significant negative
impacts on patients' quality of life5. Chronic diseases, due to their intrinsic nature, are
particularly susceptible to non‐adhesion5. According to the World Health Organization (WHO),
inadequate adherence to drug therapy in chronic diseases is considered a worldwide problem








The sample sizes ranged from 34 to 2595 chronic patients (Table 1)
and were mostly non‐probabilistic (convenience) (75%) (Figure 5).
The most common pathologies were: diabetes, hypertension,
diabetic retinopathy and hypercholesterolemia (34.1%); psychiatric




diseases adhere to drug treatments. While precarious access to health care, lack of adequate
diagnosis and limited access to medicines, and poor adherence to drug therapy in developing
countries are conditions that challenge successful chronic disease 7.
To present a review of the literature on the subject "Adherence to therapy" in outpatients.
















Variable Sample Data collection (Months) Adherence rate (%) Adherence score
Table 1  – Descriptive measures related to the sample, data collection period,  rate and score adherence
A search was carried out in the Medline database and the combinations of words Medication,
Adherence and Outpatients were used for the period from 2010 to 2017. including only articles
that adopted the Morisky Medication Adherence Scale (MMAS) to measure adherence to
medication and studies developed in hospital context. In addition, articles with non‐
conventional therapies were excluded, namely those that resorted to the use of medicinal
plants. Information was collected on the place of the study, period, type of study, sample,
Methods
Taking into account the variable "adherence to therapeutic", 84.5% of the studies used a
dichotomous variable. The others determined the score (mean with associated standard
deviation) In general therapeutic adherence was low Considering the adherence rates the
Number studies 42 31 37 7
Missing 2 13 0 0
Mean 349,0 8,23 53,97 6,47
Median 199,5 6 54 6,5
Mode 112 4 47,3 5,9
Std Deviation 448 6,75 16,6 0,374
Minimum 34 1 7,4 5,9
Maximum 2595 36 83 6,96
pathology, adherence to therapy in terms of rate or score (mean) and factors identified as
being associated with non‐adherence to therapy.
Results
The search retrieved 461 publications and 44 were included in the analysis of which 11.4% (5)
were abstracts and 88.6% (39) were full‐text articles (Figure 1). The included studies are from
Europe, Asia, Africa and America (Figure 2). Most of the studies were observational (84.1%)
. , . ,
lowest were recorded in the treatment of hypercholesterolemia (7.4%) and the highest was
recorded in the treatment of hypertension in patients with apnea (83%) (Table 1). It should be






















The factors most commonly referred to as being associated with non‐adherence were age,
forgetfulness, lack of social support, the complexity of intake and stopping medication when




























Interventional studies show significant improvements in adherence, comparing the situation
before and after the intervention. Therefore, it is a priority to implement measures that
improve adherence to therapy.
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